Cargando…

Adherence rates and health care costs in Crohn’s disease patients receiving certolizumab pegol with and without home health nurse assistance: results from a retrospective analysis of patient claims and home health nurse data

BACKGROUND: Patient support programs have a positive effect on adherence to therapy. Certolizumab pegol (CZP) is a tumor necrosis factor antagonist for the treatment of Crohn’s disease. OBJECTIVES: To assess, using real-world claims data, whether home health nurse assistance had an effect on patient...

Descripción completa

Detalles Bibliográficos
Autores principales: Wolf, Douglas C, Jaganathan, Srihari, Burudpakdee, Chakkarin, Seetasith, Arpamas, Low, Robert, Lee, Edward, Gucky, Jay, Yassine, Mohamed, Schwartz, David A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5973629/
https://www.ncbi.nlm.nih.gov/pubmed/29872272
http://dx.doi.org/10.2147/PPA.S148777
_version_ 1783326671209758720
author Wolf, Douglas C
Jaganathan, Srihari
Burudpakdee, Chakkarin
Seetasith, Arpamas
Low, Robert
Lee, Edward
Gucky, Jay
Yassine, Mohamed
Schwartz, David A
author_facet Wolf, Douglas C
Jaganathan, Srihari
Burudpakdee, Chakkarin
Seetasith, Arpamas
Low, Robert
Lee, Edward
Gucky, Jay
Yassine, Mohamed
Schwartz, David A
author_sort Wolf, Douglas C
collection PubMed
description BACKGROUND: Patient support programs have a positive effect on adherence to therapy. Certolizumab pegol (CZP) is a tumor necrosis factor antagonist for the treatment of Crohn’s disease. OBJECTIVES: To assess, using real-world claims data, whether home health nurse assistance had an effect on patients’ adherence to CZP and to measure its impact on health care use and costs. METHODS: A retrospective analysis of medical and pharmacy claims data from the IQVIA Real-World Data Adjudicated Claims Database was conducted using data from January 1, 2007 through September 30, 2015. CZP patients with Crohn’s disease were eligible to receive self-administration instructions from a nurse or nurse-administered CZP injections, or both. These services were provided by CIMplicity(®), a home health nurse program sponsored by UCB Pharma. Cohorts were based on patients with and without nurse assistance and were matched based on gender and categorical age. Adherence to CZP was determined using the medication possession ratio (MPR) and proportion of days covered (PDC). A Kaplan–Meier analysis was performed to compare time to discontinuation of CZP between the two cohorts. Multivariate regression analyses were performed, adjusting for additional covariates to compare the effect of CZP with and without nurse assistance on hospitalization and total health care costs. RESULTS: Patients with at least 12 months of continuous enrollment post-index date were evaluated for adherence to CZP (n=276 in each cohort). The mean and median PDC and MPR values were higher with nurse assistance than without. Time to discontinuation was significantly longer in patients who received CZP with nurse assistance than without (P=0.0004). Results from the multivariate analyses showed a significant reduction in all-cause hospitalization (−55.8%; P=0.0026) and total health care costs (−14.3%; P=0.0045) with nurse assistance. CONCLUSION: This analysis suggests that home health nurse assistance increases adherence to CZP and reduces health care costs in patients with Crohn’s disease.
format Online
Article
Text
id pubmed-5973629
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-59736292018-06-05 Adherence rates and health care costs in Crohn’s disease patients receiving certolizumab pegol with and without home health nurse assistance: results from a retrospective analysis of patient claims and home health nurse data Wolf, Douglas C Jaganathan, Srihari Burudpakdee, Chakkarin Seetasith, Arpamas Low, Robert Lee, Edward Gucky, Jay Yassine, Mohamed Schwartz, David A Patient Prefer Adherence Original Research BACKGROUND: Patient support programs have a positive effect on adherence to therapy. Certolizumab pegol (CZP) is a tumor necrosis factor antagonist for the treatment of Crohn’s disease. OBJECTIVES: To assess, using real-world claims data, whether home health nurse assistance had an effect on patients’ adherence to CZP and to measure its impact on health care use and costs. METHODS: A retrospective analysis of medical and pharmacy claims data from the IQVIA Real-World Data Adjudicated Claims Database was conducted using data from January 1, 2007 through September 30, 2015. CZP patients with Crohn’s disease were eligible to receive self-administration instructions from a nurse or nurse-administered CZP injections, or both. These services were provided by CIMplicity(®), a home health nurse program sponsored by UCB Pharma. Cohorts were based on patients with and without nurse assistance and were matched based on gender and categorical age. Adherence to CZP was determined using the medication possession ratio (MPR) and proportion of days covered (PDC). A Kaplan–Meier analysis was performed to compare time to discontinuation of CZP between the two cohorts. Multivariate regression analyses were performed, adjusting for additional covariates to compare the effect of CZP with and without nurse assistance on hospitalization and total health care costs. RESULTS: Patients with at least 12 months of continuous enrollment post-index date were evaluated for adherence to CZP (n=276 in each cohort). The mean and median PDC and MPR values were higher with nurse assistance than without. Time to discontinuation was significantly longer in patients who received CZP with nurse assistance than without (P=0.0004). Results from the multivariate analyses showed a significant reduction in all-cause hospitalization (−55.8%; P=0.0026) and total health care costs (−14.3%; P=0.0045) with nurse assistance. CONCLUSION: This analysis suggests that home health nurse assistance increases adherence to CZP and reduces health care costs in patients with Crohn’s disease. Dove Medical Press 2018-05-21 /pmc/articles/PMC5973629/ /pubmed/29872272 http://dx.doi.org/10.2147/PPA.S148777 Text en © 2018 Wolf et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Original Research
Wolf, Douglas C
Jaganathan, Srihari
Burudpakdee, Chakkarin
Seetasith, Arpamas
Low, Robert
Lee, Edward
Gucky, Jay
Yassine, Mohamed
Schwartz, David A
Adherence rates and health care costs in Crohn’s disease patients receiving certolizumab pegol with and without home health nurse assistance: results from a retrospective analysis of patient claims and home health nurse data
title Adherence rates and health care costs in Crohn’s disease patients receiving certolizumab pegol with and without home health nurse assistance: results from a retrospective analysis of patient claims and home health nurse data
title_full Adherence rates and health care costs in Crohn’s disease patients receiving certolizumab pegol with and without home health nurse assistance: results from a retrospective analysis of patient claims and home health nurse data
title_fullStr Adherence rates and health care costs in Crohn’s disease patients receiving certolizumab pegol with and without home health nurse assistance: results from a retrospective analysis of patient claims and home health nurse data
title_full_unstemmed Adherence rates and health care costs in Crohn’s disease patients receiving certolizumab pegol with and without home health nurse assistance: results from a retrospective analysis of patient claims and home health nurse data
title_short Adherence rates and health care costs in Crohn’s disease patients receiving certolizumab pegol with and without home health nurse assistance: results from a retrospective analysis of patient claims and home health nurse data
title_sort adherence rates and health care costs in crohn’s disease patients receiving certolizumab pegol with and without home health nurse assistance: results from a retrospective analysis of patient claims and home health nurse data
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5973629/
https://www.ncbi.nlm.nih.gov/pubmed/29872272
http://dx.doi.org/10.2147/PPA.S148777
work_keys_str_mv AT wolfdouglasc adherenceratesandhealthcarecostsincrohnsdiseasepatientsreceivingcertolizumabpegolwithandwithouthomehealthnurseassistanceresultsfromaretrospectiveanalysisofpatientclaimsandhomehealthnursedata
AT jaganathansrihari adherenceratesandhealthcarecostsincrohnsdiseasepatientsreceivingcertolizumabpegolwithandwithouthomehealthnurseassistanceresultsfromaretrospectiveanalysisofpatientclaimsandhomehealthnursedata
AT burudpakdeechakkarin adherenceratesandhealthcarecostsincrohnsdiseasepatientsreceivingcertolizumabpegolwithandwithouthomehealthnurseassistanceresultsfromaretrospectiveanalysisofpatientclaimsandhomehealthnursedata
AT seetasitharpamas adherenceratesandhealthcarecostsincrohnsdiseasepatientsreceivingcertolizumabpegolwithandwithouthomehealthnurseassistanceresultsfromaretrospectiveanalysisofpatientclaimsandhomehealthnursedata
AT lowrobert adherenceratesandhealthcarecostsincrohnsdiseasepatientsreceivingcertolizumabpegolwithandwithouthomehealthnurseassistanceresultsfromaretrospectiveanalysisofpatientclaimsandhomehealthnursedata
AT leeedward adherenceratesandhealthcarecostsincrohnsdiseasepatientsreceivingcertolizumabpegolwithandwithouthomehealthnurseassistanceresultsfromaretrospectiveanalysisofpatientclaimsandhomehealthnursedata
AT guckyjay adherenceratesandhealthcarecostsincrohnsdiseasepatientsreceivingcertolizumabpegolwithandwithouthomehealthnurseassistanceresultsfromaretrospectiveanalysisofpatientclaimsandhomehealthnursedata
AT yassinemohamed adherenceratesandhealthcarecostsincrohnsdiseasepatientsreceivingcertolizumabpegolwithandwithouthomehealthnurseassistanceresultsfromaretrospectiveanalysisofpatientclaimsandhomehealthnursedata
AT schwartzdavida adherenceratesandhealthcarecostsincrohnsdiseasepatientsreceivingcertolizumabpegolwithandwithouthomehealthnurseassistanceresultsfromaretrospectiveanalysisofpatientclaimsandhomehealthnursedata